The assay can be used in conjunction with other laboratory and clinical findings to differentiate IBD from irritable bowel syndrome, the firm said.
The fully automated, random access calprotectin assay can help clinicians differentiate irritable bowel disease from irritable bowel syndrome.
The researchers plan to profile patients with both Adaptive Biotechnologies' ImmunoSeq platform and 10x Genomics' single-cell immune repertoire profiling technology.
The firm's recent funding round will support its CLIA-certified laboratory that opened last year and the launch of its first RNA-based diagnostic test.
The Dutch firm expects its product to be the first commercial test on the market to diagnose IBD by analyzing a patient's gut microbiome.
The Norwegian microbiome-focused clinical diagnostics company has ceded commercialization rights in certain undisclosed territories to Bio-Rad as part of the deal.